Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Trading 05-16 11:10:25 EDT

3.33

-0.05

-1.48%

High3.36	Low3.29	Vol65.93K
Open3.35	D1 Closing3.38	Amplitude2.07%
Mkt Cap73.98M	Tradable Cap59.19M	Total Shares22.22M
T/O218.60K	T/O Rate0.37%	Tradable Shares17.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":3.33,"timestamp":1715872203872,"preClose":3.38,"halted":0,"volume":65927,"delay":0,"floatShares":17774649,"shares":22217265,"eps":-1.704093,"marketStatus":"Trading","change":-0.05,"latestTime":"05-16 11:10:25 EDT","open":3.35,"high":3.36,"low":3.29,"amount":218598.17544700002,"amplitude":0.02071,"askPrice":3.35,"askSize":100,"bidPrice":3.32,"bidSize":117,"shortable":3,"etf":0,"ttmEps":-1.704093,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715889600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.38,"preHourTrading":{"tag":"盘前","latestPrice":3.3499,"preClose":3.38,"latestTime":"09:29 EDT","volume":4749,"amount":15714.638083500002,"timestamp":1715866174255},"postHourTrading":{"tag":"盘后","latestPrice":3.36,"preClose":3.38,"latestTime":"17:52 EDT","volume":8750,"amount":29542.112,"timestamp":1715809966889},"volumeRatio":0.699887},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2434033858","title":"Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434033858","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434033858?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:12","pubTimestamp":1715343172,"startTime":"0","endTime":"0","summary":"In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-buy-rating-for-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-buy-rating-for-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434026721","title":"Tempest Therapeutics reports Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434026721","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434026721?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:46","pubTimestamp":1715291200,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics press release : Q1 net loss and net loss per share were $7.9 million and $0.36. Ended the quarter with $32.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023. Research and development expenses for the quarter were $4.3 million.  General and administrative expenses for the quarter were $3.6 million. Based on its current cash and operating plan, the company said it expects to have sufficient resources to fund operations into the second quarter of 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104303-tempest-therapeutics-reports-q1-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2433802427","title":"Tempest Therapeutics Inc    expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2433802427","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433802427?lang=en_us&edition=fundamental","pubTime":"2024-05-06 20:14","pubTimestamp":1714997646,"startTime":"0","endTime":"0","summary":"* Tempest Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 8 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428632157","title":"Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2428632157","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428632157?lang=en_us&edition=fundamental","pubTime":"2024-04-18 01:26","pubTimestamp":1713374816,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confi","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1921142496/image_1921142496.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1921142496/image_1921142496.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4684277-tempest-therapeutics-multiple-2024-catalysts-make-this-a-must-watch","is_publish_highlight":false,"gpt_icon":0},{"id":"2427788466","title":"BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene","url":"https://stock-news.laohu8.com/highlight/detail?id=2427788466","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2427788466?lang=en_us&edition=fundamental","pubTime":"2024-04-16 01:48","pubTimestamp":1713203309,"startTime":"0","endTime":"0","summary":"April 15 (Reuters) - The Dow outpaced Wall Street peers on Monday, boosted by robust gains in Goldman Sachs, while rising Treasury yields following stronger-than-anticipated retail sales data kept gai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426198392","title":"Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2426198392","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2426198392?lang=en_us&edition=fundamental","pubTime":"2024-04-09 12:00","pubTimestamp":1712635200,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., April  09, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therape","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/09/2859912/0/en/Tempest-Reports-New-Preclinical-Data-for-TPST-1120-in-RCC-at-the-AACR-Annual-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424539360","title":"Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2424539360","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424539360?lang=en_us&edition=fundamental","pubTime":"2024-04-04 12:00","pubTimestamp":1712203200,"startTime":"0","endTime":"0","summary":"TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data, Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/04/2857718/0/en/Tempest-Announces-Publication-of-Positive-Data-from-Phase-1-Trial-of-TPST-1120-in-Patients-with-Advanced-Solid-Tumors-in-Journal-of-Cancer-Research-Communications.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2424312820","title":"PUPR Ministry Allots Over Rp35 trillion for IKN Development in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2424312820","media":"Tempo","top":-1,"share":"https://ttm.financial/m/news/2424312820?lang=en_us&edition=fundamental","pubTime":"2024-04-02 11:39","pubTimestamp":1712029165,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -PUPR Minister Basuki Hadimuljono readies Rp35.45 trillion for the development of Nusantara Capital City  with the largest allocation for transportation infrastructure development.\"The allocation for  of Highways is Rp16.67 trillion to continue the construction of the West and East Sides of the National Axis Road, District Feeder Roads in the IKN area, Toll Road Sections 3A, 3B, 5A, 5B, 6A, 6B, and 6C1, as well as the airstrip side of the IKN Airport,\" the Public Works and Housing Minister said in Jakarta on Monday.The Directorate General of Human Settlements has been allotted Rp11.44 trillion to build supporting facilities for drinking water supply systems , wastewater treatment plants , integrated waste treatment sites , as well as the Presidential Palace area, and ministerial offices.","market":"other","thumbnail":"https://statik.tempo.co/data/2024/03/22/id_1289639/1289639_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2024/03/22/id_1289639/1289639_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://en.tempo.co/read/1852287/pupr-ministry-allots-over-rp35-trillion-for-ikn-development-in-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2421057676","title":"Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2421057676","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2421057676?lang=en_us&edition=fundamental","pubTime":"2024-03-21 14:01","pubTimestamp":1711000880,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics, Inc. (TPST) has disclosed a new risk, in the Innovation / R&D category. Tempest Therapeutics, Inc., a clinical-stage biotechn...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-struggles-a-financial-storm-brews-amidst-mounting-losses-and-development-hurdles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tempest-therapeutics-struggles-a-financial-storm-brews-amidst-mounting-losses-and-development-hurdles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420745338","title":"Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2420745338","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420745338?lang=en_us&edition=fundamental","pubTime":"2024-03-20 20:00","pubTimestamp":1710936033,"startTime":"0","endTime":"0","summary":"* Tempest Therapeutics Inc    reported a quarterly adjusted loss of 38 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -63 c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420659710","title":"Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2420659710","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420659710?lang=en_us&edition=fundamental","pubTime":"2024-03-20 19:16","pubTimestamp":1710933418,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report) today and set a price target of $8.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420254710","title":"Tempest Therapeutics (TPST) Receives a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2420254710","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420254710?lang=en_us&edition=fundamental","pubTime":"2024-03-20 19:16","pubTimestamp":1710933406,"startTime":"0","endTime":"0","summary":"In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tempest-therapeutics-tpst-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tempest-therapeutics-tpst-receives-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420784235","title":"BRIEF-Tempest Therapeutics Says Ended Year With $39.2 Million In Cash And Cash Equivalents","url":"https://stock-news.laohu8.com/highlight/detail?id=2420784235","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420784235?lang=en_us&edition=fundamental","pubTime":"2024-03-20 06:21","pubTimestamp":1710886883,"startTime":"0","endTime":"0","summary":"March 19 (Reuters) - Tempest Therapeutics Inc   :   * TEMPEST THERAPEUTICS INC - ENDED YEAR WITH $39.2 MILLION IN CASH AND CASH EQUIVALENTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420368783","title":"Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents","url":"https://stock-news.laohu8.com/highlight/detail?id=2420368783","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2420368783?lang=en_us&edition=fundamental","pubTime":"2024-03-20 04:40","pubTimestamp":1710880818,"startTime":"0","endTime":"0","summary":"Financial Results\n\nYear End 2023\n\n\n\tTempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.  The increase was primarily due to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37833500/tempest-fy23-eps-1-91-vs-3-09-yoy-ended-the-year-with-39-2m-in-cash-and-cash-equivalents","is_publish_highlight":false,"gpt_icon":0},{"id":"2420948783","title":"Tempest Therapeutics GAAP EPS of -$1.91 beats by $0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2420948783","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420948783?lang=en_us&edition=fundamental","pubTime":"2024-03-20 04:37","pubTimestamp":1710880662,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics press release  : FY  GAAP EPS of -$1.91  beats by $0.03.Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.The increase was primarily due to proceeds from the issuance of common stock of $35.6 million from the at-the-market offering program, offset by cash used in operating activities.More on Tempest Therapeutics  Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeutics","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4081347-tempest-therapeutics-gaap-eps-of-1_91-beats-0_03","is_publish_highlight":false,"gpt_icon":0},{"id":"2420915788","title":"Press Release: Tempest Reports Year End 2023 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2420915788","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2420915788?lang=en_us&edition=fundamental","pubTime":"2024-03-20 04:25","pubTimestamp":1710879900,"startTime":"0","endTime":"0","summary":"-- Announced positive randomized first-line HCC data showing superiority of. TPST-1120 combination therapy across multiple study endpoints compared to. -- Reported new biomarker data in two important subpopulations, PD-L1. negative and b-catenin mutant patients, consistent with MoA of TPST-1120. -- Preparing to move TPST-1120 into a pivotal Phase 3 trial in HCC and. \"2023 was a transformative year for Tempest. We announced strong positive randomized data showing the benefit of TPST-1120 combination therapy compared to standard-of-care in first-line liver cancer,\" said Stephen Brady, president and chief executive officer of Tempest. \"These data also showed the predicted positive effect of TPST-1120 in two subpopulations that are common in liver cancer, i.e., patients with PD-L1 negative and cold tumors, as well as patients with a b-catenin mutation, and we believe set up the program for a pivotal Phase 3 trial. We look forward to 2024 as the year Tempest evolves towards becoming a late-","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2420421495","title":"Tempest Therapeutics Inc    expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2420421495","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420421495?lang=en_us&edition=fundamental","pubTime":"2024-03-18 19:02","pubTimestamp":1710759740,"startTime":"0","endTime":"0","summary":"* Tempest Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on March 20 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419410976","title":"U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2419410976","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419410976?lang=en_us&edition=fundamental","pubTime":"2024-03-14 14:31","pubTimestamp":1710397916,"startTime":"0","endTime":"0","summary":"March 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ashland, Oportun Financial and Palomar Holdings on Thursday.   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418955627","title":"Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2418955627","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2418955627?lang=en_us&edition=fundamental","pubTime":"2024-03-12 23:05","pubTimestamp":1710255914,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $47.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-tempest-therapeutics-amid-strong-tpst-1120-preclinical-and-financial-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-tempest-therapeutics-amid-strong-tpst-1120-preclinical-and-financial-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2418533064","title":"Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types","url":"https://stock-news.laohu8.com/highlight/detail?id=2418533064","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2418533064?lang=en_us&edition=fundamental","pubTime":"2024-03-12 12:00","pubTimestamp":1710216000,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  12, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therape","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/12/2844489/0/en/Tempest-Presents-New-Data-at-the-SITC-2024-Spring-Scientific-Meeting-Supporting-Potent-Anti-tumor-Activity-of-TPST-1120-in-Multiple-Cancer-Types.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":0.012},{"period":"3month","weight":-0.1508},{"period":"6month","weight":-0.0231},{"period":"1year","weight":0.665},{"period":"ytd","weight":-0.2318}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.011023},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.013716},{"month":3,"riseRate":0.545455,"avgChangeRate":0.034268},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.129414},{"month":5,"riseRate":0.5,"avgChangeRate":0.020398},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.115881},{"month":7,"riseRate":0.181818,"avgChangeRate":-0.018567},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.072863},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.081049},{"month":10,"riseRate":0.545455,"avgChangeRate":1.150336},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.037362},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.053509}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}